DATASET RE-READ 2026-11-2042 PROGRAMSNEXLIFE PRICES READ 2026-11-20EVERY FIGURE CARRIES ITS READ DATE
TopGLP1Providers.comverified price index
DATED PRICES

FDA drug shortage list

The official registry whose entries create the legal exception allowing compounded copies of approved drugs. Tirzepatide left it in late 2024 and semaglutide in February 2025 — the two delistings from which every subsequent contraction of this market flows.

Released · Last reviewed · how we verify

Where the term bites in the current data: our dated tirzepatide reads run $129–$399/month all-in and semaglutide $99–$299 (newest reads; NexLife November 20, 2026), and nearly every dollar of those spreads is explained by the vocabulary on this glossary’s pages — memberships inside or outside headline figures, flat versus tiered ladders, prepaid terms dressed as monthly prices, evidence flags separating captures from claims. Reading this market is mostly a matter of knowing which of those words applies to the number in front of you.

Like every entry here, this definition is written against the live dataset rather than in the abstract: when the market moves, the interpolated figures in this glossary move with it on the next build, which is the only way definitions about a repricing market stay true.

See the term in action across the price database and the methodology.

All-in priceMaintenance-dose basisDose-flat pricingDose-tiered pricingMembership feePrepaid term

Primary sources

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.